The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Current scenario and future applicability of antivirals against herpes zoster

  • Sang Hun, Kim (Department of Anesthesiology and Pain Medicine, Chosun University Hospital)
  • Received : 2022.11.30
  • Accepted : 2022.12.15
  • Published : 2023.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Herpes zoster (HZ) is a common disease in the aging population and immunocompromised individuals, with a lifetime risk of 20%-30% that increases with age. HZ is caused by reactivation of the varicella-zoster virus (VZV), which remains latent in the spinal dorsal root ganglia and cranial sensory ganglia after resolution of the primary VZV infection. The main focus of HZ management is rapid recovery from VZV infection as well as the reduction and prevention of zoster-associated pain (ZAP) and postherpetic neuralgia (PHN). The use of antivirals against VZV is essential in the treatment of HZ. However, limited antivirals are only licensed clinically for the treatment of HZ, including acyclovir, valacyclovir, famciclovir, brivudine, and amenamevir. Fortunately, some new antivirals against different types of Herpesviridae have been investigated and suggested as novel drugs against VZV. Therefore, this review focuses on discussing the difference in efficacy and safety in the currently licensed antivirals for the treatment of HZ, the applicability of future novel antivirals against VZV, and the preventive or therapeutic effects of these antivirals on ZAP or PHN.

Keywords

Acknowledgement

This study was supported by a research fund from the Chosun University Hospital 2022 (funding number: 2022-15).

References

  1. Jeon YH. Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain 2015; 28: 177-84. https://doi.org/10.3344/kjp.2015.28.3.177
  2. Cohen EJ, Jeng BH. Herpes zoster: a brief definitive review. Cornea 2021; 40: 943-9. https://doi.org/10.1097/ICO.0000000000002754
  3. Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis 2020; 7: ofaa005. https://doi.org/10.1093/ofid/ofaa005
  4. Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses 2022; 14: 192. https://doi.org/10.3390/v14020192
  5. Majewska A, Mlynarczyk-Bonikowska B. 40 Years after the registration of acyclovir: do we need new anti-herpetic drugs? Int J Mol Sci 2022; 23: 3431. https://doi.org/10.3390/ijms23073431
  6. Friesen KJ, Alessi-Severini S, Chateau D, Falk J, Bugden S. The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study. Clinicoecon Outcomes Res 2016; 8: 207-14.
  7. De Clercq E. FV-100 for the treatment of varicellavirus (VZV) infections: quo vadis? Viruses 2022; 14: 770. https://doi.org/10.3390/v14040770
  8. Andrei G, Snoeck R. Advances and perspectives in the management of varicella-zoster virus infections. Molecules 2021; 26: 1132. https://doi.org/10.3390/molecules26041132
  9. Tyring SK, Plunkett S, Scribner AR, Broker RE, Herrod JN, Handke LT, et al. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, doubleblind, active-controlled trial. J Med Virol 2012; 84:1224-32. https://doi.org/10.1002/jmv.23329
  10. De SK, Hart JC, Breuer J. Herpes simplex virus and varicella zoster virus: recent advances in therapy. Curr Opin Infect Dis 2015; 28: 589-95. https://doi.org/10.1097/qco.0000000000000211
  11. Zhu J, Luo G, He Q, Yao M. Evaluation of the efficacy of unipolar and bipolar spinal dorsal root ganglion radiofrequency thermocoagulation in the treatment of postherpetic neuralgia. Korean J Pain 2022; 35:114-23. https://doi.org/10.3344/kjp.2022.35.1.114
  12. Singh G, Song S, Choi E, Lee PB, Nahm FS. Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia. Korean J Pain 2020; 33: 201-7. https://doi.org/10.3344/kjp.2020.33.3.201
  13. Kim SY, Kim DG, Park YM, Jeon YH. Psoas compartment block for treatment of motor weakness and pain following herpes zoster. Korean J Pain 2017; 30:62-5. https://doi.org/10.3344/kjp.2017.30.1.62
  14. Poole CL, James SH. Antiviral therapies for herpesviruses: current agents and new directions. Clin Ther 2018; 40: 1282-98. https://doi.org/10.1016/j.clinthera.2018.07.006
  15. Sauerbrei A. Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections. Eur J Clin Microbiol Infect Dis 2016; 35: 723-34. https://doi.org/10.1007/s10096-016-2605-0
  16. Yaldiz M, Solak B, Kara RO, Cosansu N, Erdem MT. Comparison of famciclovir, valaciclovir, and brivudine treatments in adult immunocompetent patients with herpes zoster. Am J Ther 2018; 25: e626-34. https://doi.org/10.1097/MJT.0000000000000436
  17. Piret J, Boivin G. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr Opin Infect Dis 2016;29: 654-62. https://doi.org/10.1097/QCO.0000000000000288
  18. Muhaj FF, George SJ, Nguyen CD, Tyring SK. Antimicrobials and resistance part II: antifungals, antivirals, and antiparasitics. J Am Acad Dermatol 2022;86: 1207-26. https://doi.org/10.1016/j.jaad.2021.11.065
  19. Shiraki K, Yasumoto S, Toyama N, Fukuda H. Amenamevir, a helicase-primase inhibitor, for the optimal treatment of herpes zoster. Viruses 2021; 13:1547. https://doi.org/10.3390/v13081547
  20. Pott Junior H, de Oliveira MFB, Gambero S, Amazonas RB. Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. Int J Infect Dis 2018; 72: 11-5. https://doi.org/10.1016/j.ijid.2018.04.4324
  21. Whitley RJ, Volpi A, McKendrick M, Wijck A, Oaklander AL. Management of herpes zoster and postherpetic neuralgia now and in the future. J Clin Virol 2010; 48 Suppl 1: S20-8. https://doi.org/10.1016/S1386-6532(10)70005-6
  22. Yeh CH, Chang KS, Huang SS, Tsay SL, Tsai JM, Wang YJ. Comparing prodrugs with acyclovir for treating postherpetic neuralgia among herpes zoster patients: a systematic review and meta-analysis. Healthcare (Basel) 2022; 10: 1181. https://doi.org/10.3390/healthcare10071181
  23. Ono F, Yasumoto S, Furumura M, Hamada T, Ishii N, Gyotoku T, et al. Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster. J Dermatol 2012; 39: 902-8. https://doi.org/10.1111/j.1346-8138.2012.01584.x
  24. Schuster AK, Harder BC, Schlichtenbrede FC, Jarczok MN, Tesarz J. Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Cochrane Database Syst Rev 2016; 11: CD011503. https://doi.org/10.1002/14651858.CD011503.pub2
  25. Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovircontrolled phase 3 study. J Dermatol 2017; 44: 1219-27. https://doi.org/10.1111/1346-8138.13948
  26. Werner RN, Nikkels AF, Marinovic B, Schafer M, Czarnecka-Operacz M, Agius AM, et al. European consensus-based (S2k) guideline on the management of herpes zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 2: treatment. J Eur Acad Dermatol Venereol 2017; 31: 20-9. https://doi.org/10.1111/jdv.13957
  27. Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician 2000; 61: 2437-44, 2447-8.
  28. Saguil A, Kane S, Mercado M, Lauters R. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician 2017; 96: 656-63.
  29. John AR, Canaday DH. Herpes zoster in the older adult. Infect Dis Clin North Am 2017; 31: 811-26. https://doi.org/10.1016/j.idc.2017.07.016
  30. Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2014; (2): CD006866.
  31. Kim J, Kim MK, Choi GJ, Shin HY, Kim BG, Kang H. Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. Korean J Pain 2021; 34: 509-33. https://doi.org/10.3344/kjp.2021.34.4.509
  32. Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, et al. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: a randomized-controlled trial. J Med Virol 2017; 89:1255-64. https://doi.org/10.1002/jmv.24750